Recently, the poly (ADP-ribose) polymerase (PARP) inhibitors olaparib[3,4] and niraparib[5], as well as the vascular endothelial growth factor (VEGF) inhibitor bevacizumab[4], have been used as maintenance therapies for ovarian cancer. Here, VEGFA is linked to ovarian cancer.